Cite
HARVARD Citation
Kulke, M. et al. (n.d.). 37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial). European journal of cancer. pp. S728-. [Online].